Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.
GlaxoSmithKline (GSK) has announced the repurchase of 501,689 of its ordinary shares as part of its ongoing buyback program. The shares, purchased through Merrill Lynch International, will be held as treasury shares. This transaction is part of a non-discretionary agreement initiated on June 4, 2025, and contributes to the total of 23,706,405 shares repurchased since that date. The buyback program aims to manage the company’s capital structure effectively, impacting the total number of voting rights, which stands at 4,073,550,458.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score is driven by strong financial performance and positive corporate events, such as strategic buybacks and executive share acquisitions. While technical indicators suggest a neutral trend, the company’s balanced valuation and positive earnings call outlook contribute to a favorable investment profile.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
Average Trading Volume: 8,874,122
Technical Sentiment Signal: Buy
Current Market Cap: £56.63B
For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.